Table 16.1
Bioactivities of gedunin or derivatives tested with respective experimental model
Bioactivities
Gedunin/Derivatives
Experimental model
Efficacy
References
Anti-cancer
Gedunin
Caco2 colon cancer cell line
16.8
lM
a
Uddin et al.
(2007)
MCF-7 breast cancer cell lines
8.84
± 0.03
lM
a
Brandt et al.
(2008)
SkBr3 breast cancer cell lines
3.22
± 0.06
lM
a
Brandt et al.
(2008)
Pancreatic cancer cell lines
Unidentified
Boopalan
et al. (2013)
ID8, ID8TaxR, A2870, C30 and CP70
ovarian cancer cell lines
0–30
lM
b
Johnson
et al. (2014)
A2870 and ID8 chemoresistant ovarian
cancer cell lines
2.5
lM (Synergizes with
cisplatin and paclitaxel)
b
Johnson
et al. (2014)
Cervical cancer cell line HeLa-PR
B and
Breast carcinoma cell lines MDA-MB-231,
MDA-MB-453, Hs578T, T47D and MCF7
0–40
lM
b
Patwardhan
et al. (2013)
Leukemia cell line HL60
5.9
lM
a
Kikuchi
et al. (2011)
Lung cancer cell line A549
>20
lM
a
Kikuchi
et al.(2011)
Stomach cancer cell line AZ521
16.9
lM
a
Kikuchi
et al. (2011)
Breast cancer cell line SK-BR-3
8.3
lM
a
Kikuchi
et al. (2011)
Melanoma cell line CRL1579
>20
lM
a
Kikuchi
et al. (2011)
Caco2 colon cancer cell line
Unidentified
Uddin et al.
(2007)
(continued)
16 An Overview of the Bioactivities of Gedunin
567